CardioVia Announces FDA Clearance for ViaOne, Opening a New Frontier in Minimally Invasive Heart-Surface Treatments

CardioVia Strengthens IP Portfolio with Medical Device Patents in Major Markets   CardioVia was granted broad patent protection across the United States, Europe, Israel, Japan and China for its unique blunt-tip concealed needle and bio-impedance navigation system.

CardioVia’s Peer-Reviewed Epicardial Access Preclinical Study in JICE Validates ViaOne’s Safety and Feasibility   A pre-clinical study published in the Journal of Interventional Cardiac Electrophysiology demonstrated the feasibility and safety of the ViaOne system in porcine models.

CardioVia’s ViaOne Selected as a Late-Breaking Clinical Trial at the Heart Rhythm Society   CardioVia’s First-in-Human clinical study of ViaOne was selected as a Late Breaking Clinical Trial at the Heart Rhythm Society (HRS) Annual Scientific Sessions.

CardioVia’s Peer-Reviewed Epicardial Access Feasibility Study Published in JACC: Clinical Electrophysiology The results of ViaOne’s First-in-Human feasibility study were published in JACC: Clinical Electrophysiology, a leading peer-reviewed medical journal.